Maham Fatima
Mon, April 27, 2026 astatine 1:22 AM CDT 2 min read
This superior is expected to supply a fiscal runway into H2 2027, supporting the advancement of 2 late-stage registrational programs and an emerging oral inhibitor. The company’s pb candidate, vonaprument, is presently being evaluated successful the ARCHER II Phase 3 proceedings for geographic atrophy/GA, with topline information anticipated successful Q4 2026. Unlike existing treatments that people downstream proteins, vonaprument utilizes an upstream C1q blockade designed to support photoreceptor neurons and sphere vision.
The programme has notably received PRIME designation from the European Medicines Agency, establishing a wide planetary regulatory way for what could beryllium the archetypal vision-preserving therapy for the millions affected by GA worldwide. Simultaneously, Annexon Inc. (NASDAQ:ANNX) is advancing tanruprubart for the attraction of Guillain-Barré Syndrome/GBS.
Annexon Inc. (NASDAQ:ANNX) is simply a clinical-stage biopharmaceutical institution advancing a level of targeted immunotherapies for neuroinflammatory and autoimmune diseases.
While we admit the imaginable of ANNX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey connected Google News.

1 day ago
1





English (CA) ·
English (US) ·
Spanish (MX) ·